Alnylam Pharmaceuticals Liabilities related to the sale of future royalties and development funding, net of current portion decreased by 0.0% to $1.47B in Q1 2026 compared to the prior quarter.
other_royalty_and_development_funding_liability_noncurrent| Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $1.33B | $1.47B | $1.47B |
| QoQ Change | — | +10.2% | -0.0% |
| YoY Change | — | +10.2% | — |
| Segment | Q4 '25 | Q1 '26 |
|---|---|---|
| Vutrisiran | $99.70M | $89.40M |
| Zilebesrian | $10.30M | $12.10M |
| Total | $1.47B | $1.47B |